Literature DB >> 22741033

A Prominin-1-Rich Pediatric Glioblastoma: Biologic Behavior Is Determined by Oxygen Tension-Modulated CD133 Expression but Not Accompanied by Underlying Molecular Profiles.

Laura K Donovan1, Nicola E Potter, Tracy Warr, Geoffrey J Pilkington.   

Abstract

Few studies on the biologic and molecular properties of pediatric glioblastoma have been performed. Until now, differential genomic analysis of CD133(+)ve and CD133(-)ve fractions has not been described in pediatric glioma. We hypothesize not only that the presence of CD133 could be the source of tumor resistance but also that maintenance of this molecule by hypoxia dictates cellular and molecular behavior. From a series of human glioblastoma biopsies investigated, only one, IN699 (from a pediatric glioblastoma), generated greater than 4% of the total cell volume as CD133(+)ve cells. Using this pediatric glioblastoma, containing unprecedented high levels of the putative brain tumor stem cell marker CD133, as a study model, we report biologic and molecular characteristics of the parent culture and of CD133(+)ve and CD133(-)ve populations derived therefrom under atmospheric and hypoxic culture conditions. Immunocytochemistry and flow cytometry were performed with antigenic markers known to characterize neural stem cells and associated glioma behavior. Behavioral analysis was carried out using proliferation, adhesion, migration, and invasion assays. Cell cycle analysis and array comparative genomic hybridization were used to assess copy number profiles for parental cells and CD133(+)ve and CD133(-)ve fractions, respectively. With regard to invasion and proliferation, CD133(+)ve and CD133(-)ve fractions were inversely proportional, with a significant increase in invasive propensity within the CD133(-)ve cells (P < .005) and a significant increase in proliferation within CD133(+)ve cells (P < .005). Our observations indicate identical genomic imbalances between CD133(+)ve and CD133(-)ve fractions. Furthermore, our research documents a direct link between decreasing oxygen tension and CD133 expression.

Entities:  

Year:  2012        PMID: 22741033      PMCID: PMC3384268          DOI: 10.1593/tlo.11337

Source DB:  PubMed          Journal:  Transl Oncol        ISSN: 1936-5233            Impact factor:   4.243


  71 in total

1.  CNS stem cells express a new class of intermediate filament protein.

Authors:  U Lendahl; L B Zimmerman; R D McKay
Journal:  Cell       Date:  1990-02-23       Impact factor: 41.582

2.  Combined activation of Ras and Akt in neural progenitors induces glioblastoma formation in mice.

Authors:  E C Holland; J Celestino; C Dai; L Schaefer; R E Sawaya; G N Fuller
Journal:  Nat Genet       Date:  2000-05       Impact factor: 38.330

3.  An embryonic origin for medulloblastoma.

Authors:  N L Valtz; T E Hayes; T Norregaard; S M Liu; R D McKay
Journal:  New Biol       Date:  1991-04

4.  Olig2-regulated lineage-restricted pathway controls replication competence in neural stem cells and malignant glioma.

Authors:  Keith L Ligon; Emmanuelle Huillard; Shwetal Mehta; Santosh Kesari; Hongye Liu; John A Alberta; Robert M Bachoo; Michael Kane; David N Louis; Ronald A Depinho; David J Anderson; Charles D Stiles; David H Rowitch
Journal:  Neuron       Date:  2007-02-15       Impact factor: 17.173

5.  The oligodendroglial lineage marker OLIG2 is universally expressed in diffuse gliomas.

Authors:  Keith L Ligon; John A Alberta; Alvin T Kho; Jennifer Weiss; Mary R Kwaan; Catherine L Nutt; David N Louis; Charles D Stiles; David H Rowitch
Journal:  J Neuropathol Exp Neurol       Date:  2004-05       Impact factor: 3.685

6.  CD133(+) and CD133(-) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles.

Authors:  Dagmar Beier; Peter Hau; Martin Proescholdt; Annette Lohmeier; Jörg Wischhusen; Peter J Oefner; Ludwig Aigner; Alexander Brawanski; Ulrich Bogdahn; Christoph P Beier
Journal:  Cancer Res       Date:  2007-05-01       Impact factor: 12.701

7.  Expression of Sox2 in mature and immature teratomas of central nervous system.

Authors:  Ji Hoon Phi; Sung-Hye Park; Sun Ha Paek; Seung-Ki Kim; Yun Jin Lee; Chul-Kee Park; Byung-Kyu Cho; Do-Hun Lee; Kyu-Chang Wang
Journal:  Mod Pathol       Date:  2007-04-27       Impact factor: 7.842

8.  Prostate cancer cells with stem cell characteristics reconstitute the original human tumor in vivo.

Authors:  Guangyu Gu; Jialing Yuan; Marcia Wills; Susan Kasper
Journal:  Cancer Res       Date:  2007-05-15       Impact factor: 12.701

9.  Immunolocalization of the oligodendrocyte transcription factor 1 (Olig1) in brain tumors.

Authors:  Biagio Azzarelli; Leticia Miravalle; Ruben Vidal
Journal:  J Neuropathol Exp Neurol       Date:  2004-02       Impact factor: 3.685

Review 10.  Glycosylation defining cancer cell motility and invasiveness.

Authors:  Masaya Ono; Senitiroh Hakomori
Journal:  Glycoconj J       Date:  2004       Impact factor: 3.009

View more
  6 in total

Review 1.  Glioma Stem Cells in Pediatric High-Grade Gliomas: From Current Knowledge to Future Perspectives.

Authors:  Marc-Antoine Da-Veiga; Bernard Rogister; Arnaud Lombard; Virginie Neirinckx; Caroline Piette
Journal:  Cancers (Basel)       Date:  2022-05-04       Impact factor: 6.575

Review 2.  CD133: to be or not to be, is this the real question?

Authors:  Elena Irollo; Giuseppe Pirozzi
Journal:  Am J Transl Res       Date:  2013-09-25       Impact factor: 4.060

Review 3.  CD133: holy of grail of neuro-oncology or promiscuous red-herring?

Authors:  L K Donovan; G J Pilkington
Journal:  Cell Prolif       Date:  2012-12       Impact factor: 6.831

Review 4.  Hypoxia Inducible Factors' Signaling in Pediatric High-Grade Gliomas: Role, Modelization and Innovative Targeted Approaches.

Authors:  Quentin Fuchs; Marina Pierrevelcin; Melissa Messe; Benoit Lhermitte; Anne-Florence Blandin; Christophe Papin; Andres Coca; Monique Dontenwill; Natacha Entz-Werlé
Journal:  Cancers (Basel)       Date:  2020-04-15       Impact factor: 6.639

5.  Pediatric glioma stem cells: biologic strategies for oncolytic HSV virotherapy.

Authors:  Gregory K Friedman; Joel Raborn; Virginia M Kelly; Kevin A Cassady; James M Markert; G Yancey Gillespie
Journal:  Front Oncol       Date:  2013-02-28       Impact factor: 6.244

6.  Voting-based cancer module identification by combining topological and data-driven properties.

Authors:  A K M Azad; Hyunju Lee
Journal:  PLoS One       Date:  2013-08-05       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.